Hana reiterated at buy by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh reiterated Hana BioSciences Inc. at its buy rating and $13 price target after the company announced the start of its multicenter phase 2 clinical trial evaluating Talvesta in adult patients with relapsed or refractory acute lymphoblastic leukemia. This trial had been expected to start in the fourth-quarter 2006. The analyst also expects near-term pipeline news flow and Zensana approval in the first half of 2007 to drive shares higher. Shares of the South San Francisco, Calif.-based development-stage biopharmaceutical company were up 25 cents, or 3.08%, at $8.37. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.